Citations

Clear

2511 citation(s) found for "Yang, Yu".

Abstract 6751: Differences in survival outcomes among metastatic colorectal cancer patients across fibroblast growth factor receptor 2 and 3 expression levels
Trujillo, Steve Soto , Yang, Yan , Bartolini, Michela, Mittal, Pooja, Torres-Gonzalez, Lesly, Shah, Unnati Hemant, Lo, Jae Ho, Goretsky, Yitzhar, Zhang, W., Venook, A., Algaze, Sandra, Millstein, Joshua , Lenz, Heinz-Josef, Torres‐Gonzalez, Lesly , Bartolini, Michela, Soni, Shivani, Mittal, Pooja , Ou, Fang‐Shu , Venook, Alan P. , Algaze, Sandra , Lenz, Heinz‐Josef

Mayo Clinic

Cancer Research | April 3, 2026 | Volume: 86 | Issue: 7_Supplement | Pages: 6751-6751

10.1158/1538-7445.am2026-6751 Get It

Abstract Introduction: Fibroblast growth factor receptor 2 and 3 (FGFR2 and FGFR3) are metabolic genes overexpressed in malignant epithelia. In colorectal cancer (CRC), intimate crosstalk between FGFR2/3 and epidermal growth factor receptor (EGFR) pathways has been suggested but is not fully elucidated. As a result, this study investigated associations between FGFR2/3 expression levels and clinical outcomes in patients with metastatic CRC (mCRC) enrolled in the phase III clinical trial CALGB /SWOG 80405. Methods: Data from 433 patients with mCRC enrolled in the CALGB/SWOG 80405 trial were analyzed. Patients received either bevacizumab (bev, n = 226) or cetuximab (cet, n = 207) plus chemotherapy as first-line treatment. Tumor RNA was extracted from FFPE samples and processed through the HiSeq 2500 (Ilumina) platform. Median overall survival (OS) and progression-free survival (PFS) curves were evaluated in all treatment subgroups and stratified according to high (H), medium (M), and low (L) FGFR 2 and 3 gene expression levels. Likelihood ratio tests, hazard ratios (HRs), and 95% confidence intervals (CIs) were calculated using Cox proportional hazards multivariate models, adjusting for age, sex, ECOG performance status, tumor location, number of metastatic sites, KRAS status, consensus molecular subtypes, and treatment arm. Results: Both FGFR2 and FGFR3 expression levels were associated with outcomes in patients treated with cetuximab. FGFR2-L tumors showed significantly longer OS compared to the M (HR = 1.04; 95%CI 0.71-1.51) and H (HR = 1.56; 95%CI 1.06-2.28) expression groups (35.7 vs. 31.2 vs. 23.7 months, p = 0.017). In contrast, FGFR3-L tumors were associated with shorter OS compared to the M (HR = 0.63; 95%CI 0.44-0.92) and H (HR = 0.59; 95%CI 0.41-0.85) expression groups (24.7 vs 32.4 vs 37.1 months, p = 0.0009). Significant differences in PFS were not observed. A nominally significant interaction was found between treatment and FGFR3 expression for both PFS (p = 0.02) and OS (p = 0.0003), but no interaction with FGFR2 expression. No significant associations were detected in patients treated with bev. Neither FGFR2 nor FGFR3 suggested to be prognostic markers after multivariate adjustment analyses. Conclusions: Our findings suggest a predictive role of FGFR3 in patients with mCRC undergoing anti-EGFR treatment. Differences in survival within the cet subgroup suggest that EGFR inhibitor efficacy may be modulated by FGFR2/3 signaling activity. Interestingly, FGFR2 and FGFR3 expressions were inversely and positively correlated with improved OS. The findings suggest that FGFR2 signaling minimizes the specific effects of cetuximab, while FGFR3 signaling amplifies its therapeutic effects. Further studies should determine whether these associations are seen in other anti-EGFR inhibitors and detail the mechanistic interaction between FGFR and EGFR pathways. Citation Format: Steve Soto Trujillo, Yan Yang, Michela Bartolini, Shivani Soni, Pooja Mittal, Fang-Shu Ou, Lesly Torres-Gonzalez, Unnati Hemant Shah, Jae Ho Lo, Yitzhar Goretsky, Wu Zhang, Alan Venook, Sandra Algaze, Joshua Millstein, Heinz-Josef Lenz. Differences in survival outcomes among metastatic colorectal cancer patients across fibroblast growth factor receptor 2 and 3 expression levels [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2026; Part 1 (Regular Abstracts); 2026 Apr 17-22; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(7 Suppl):Abstract nr 6751.
Abstract 7636: A rare multipotent peg-like epithelial cell is a candidate cell-of-origin for high-grade serous ovarian cancer
Yang, Wenmei, Zhao, Hui , Feng, Liang, Song, Jianning, Schaufelberger, Kenneth, Weroha, S. John, Gaspar-Maia, Alexandre, Bakkum-Gamez, Jamie, Ritting, Megan L. , Aalam, Syed Mohammed Musheer , Dumbravă, Mihai , Ismail, Wazim Mohammed , Weroha, S. John, Kaufmann, Scott H. , Gaspar‐Maia, Alexandre , Sherman, Mark E. , Bakkum‐Gamez, Jamie N. , Kannan, Nagarajan

Mayo Clinic

Cancer Research | April 3, 2026 | Volume: 86 | Issue: 7_Supplement | Pages: 7636-7636

10.1158/1538-7445.am2026-7636 Get It

Abstract High-grade serous ovarian cancer (HGSOC), the most prevalent and lethal ovarian cancer subtype, is typically diagnosed at an advanced stage due to the absence of effective early detection strategies. Mounting evidence indicates that HGSOC originates from the fallopian tube (FT), particularly from secretory epithelial cells in the fimbria. However, incomplete understanding of the cellular and molecular origins of HGSOC continues to hinder early interception efforts. To address this, we established a clinically and genetically annotated living FT organoid biobank at Mayo Clinic, representing over 200 patient donors. Using optimized enrichment protocols, we isolated FT epithelial stem/progenitor cells from tissue and Tao brushings, generating organoids independent of anatomical site or laterality that recapitulate native FT epithelial architecture and lineage differentiation. We applied integrated multi-omic analyses, including single-cell RNA sequencing, single-nucleus RNA/ATAC sequencing, and bulk RNA-seq, across fresh cells and organoids. Integration with public datasets produced the largest single-cell atlas of normal and high-risk FTs to date. This analysis defined high-specificity gene signatures for secretory and multiciliated lineages that outperform canonical lineage markers (e.g. PAX8, FOXJ1), identified lineage-defining transcription factors and regulatory networks, and showed concordant protein expression in the human FT epithelium. Notably, subcluster-level analysis revealed a rare hybrid epithelial-mesenchymal population transcriptionally and proteomically aligned with the mesenchymal-like subtype of HGSOC. Spatial immunoprofiling demonstrated that these cells express multiple defining markers and reside above the basement membrane, intercalated between epithelial cells and lack luminal contact, reminiscent of the histologically described peg cell population. Comparative analyses with fetal mesonephric tissues uncovered developmental parallels, and this population was stably maintained in 3D organoid cultures, providing a robust ex-vivo model to study early transformation. Together, our findings identify a rare, multipotent epithelial population with mesenchymal features as a candidate origin for mesenchymal-like HGSOC and establish the FT organoid biobank as a powerful platform for mechanistic and translational studies in ovarian carcinogenesis. Citation Format: Megan L. Ritting, Wenmei Yang, Syed Mohammed Musheer Aalam, Hui Zhao, Liang Feng, Jianning Song, Mihai G. Dumbrava, Wazim M. Ismail, Kenneth Schaufelberger, S. John Weroha, Scott H. Kaufmann, Alexandre Gaspar-Maia, Mark E. Sherman, Jamie N. Bakkum-Gamez, Nagarajan Kannan. A rare multipotent peg-like epithelial cell is a candidate cell-of-origin for high-grade serous ovarian cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2026; Part 1 (Regular Abstracts); 2026 Apr 17-22; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(7 Suppl):Abstract nr 7636.
Abstract 1011: Correlation of mitophagy related genes expression and clinical outcome in metastatic colorectal cancer patients enrolled in CALGB (Alliance)/SWOG 80405
Yang, Yan , Bartolini, Michela, Mittal, Pooja, Torres-Gonzalez, Lesly, Shah, Unnati Hemant, Lo, Jae Ho, Trujillo, Steve Soto , Goretsky, Yitzhar, Zhang, W., Algaze, Sandra, Millstein, Joshua , Lenz, Heinz‐Josef , Torres‐Gonzalez, Lesly , Soni, Shivani, Ou, Fang‐Shu , Venook, Alan P. , Algaze, Sandra

Mayo Clinic

Cancer Research | April 3, 2026 | Volume: 86 | Issue: 7_Supplement | Pages: 1011-1011

10.1158/1538-7445.am2026-1011 Get It

Abstract Background. Mitophagy plays a crucial role in removing dysfunctional mitochondria to maintain cellular homeostasis but also has been implicated in cancer tumorigenesis. Previously, we showed that genetic variation in mitophagy pathway genes holds a predictive value in metastatic CRC (mCRC) patients (pts) treated with bevacizumab-based chemotherapy. In this study, we analyzed the correlation between tumor expression profiles of genes associated with PINK1/Parkin and BNIP3/NIX/FUNDC1 mitophagy pathways with clinical outcome in a large phase III randomized clinical trial CALGB SWOG 80405. Method. We analyzed 433 pts with mCRC treated with first-line chemotherapy in combination with the targeted agents bevacizumab (Bev, n = 226) or cetuximab (Cet, n = 207). Tumor RNA isolated from FFPE samples was sequenced using the HiSeq 2500 platform (Illumina). Median Overall survival (mOS) and median progression-free survival (mPFS) were compared across pts groups divided into high, medium, and low tertiles based on mitophagy-related gene (BNIP3, BNIP3L, PINK1, PRKN) expression levels. Likelihood ratio tests, hazard ratios (HRs), and 95% confidence intervals (CIs) were calculated using multivariable Cox proportional hazards models, adjusting for age, sex, ECOG performance status, tumor location, number of metastatic sites, KRAS status, Consensus Molecular Subtypes, and treatment arm. Results: Overall, BNIP3L demonstrated significant prognostic value for both PFS and OS after adjustment for multiple testing (false discovery rate [FDR] < 0.05). Tumors with low BNIP3L expression showed longer PFS and OS compared to those with medium or high expression levels (mPFS 14.8 vs. 10.0 vs. 9.2 months, HR 1.16, 95% CI 1.04 - 1.29p = 0.0182; mOS: 37.4 vs. 30.2 vs. 24.4 months, HR 1.22, 95% CI 1.09 - 1.38, p = 0.0036), independent of treatment. In pts treated with Cet, high PRKN expression was associated with improved PFS and OS (mPFS: 8.9 vs. 10.3 vs. 14.6 months, HR 0.79; 95% CI 0.69 - 0.91, p = 7.3e-05; mOS: 21.2 vs. 27.7 vs. 41.1 months, HR 0.87; 95% CI 0.75 - 1.01, p = 0.00084), whereas low PINK1 expression was significantly associated with longer OS (mOS: 24.9 vs. 30.9 vs. 39.2 months, HR 1.23; 95% CI 1.04 -1.46, p = 0.013). No significant associations were observed in Bev-treated patients for PRKN or PINK1. No significant results were found for BNIP3 expression analysis. Conclusion. Mitophagy is a crucial player in CRC biology due to its tumor-intrinsic (mitochondrial bioenergetics) and microenvironment (interacts with immune components) effects. Our study highlights the prognostic value of BNIP3L and predictive potential of PINK1 and PRKN, suggesting a potential combinatorial therapeutic approach using mitochondrial targeting drugs and targeted agents e.g Cet, which warrants further investigation. Support: Genentech; Clinicaltrials.gov Identifier: NCT00265850 Citation Format: Shivani Soni, Yan Yang, Michela Bartolini, Pooja Mittal, Fang-Shu Ou, Lesly Torres-Gonzalez, Unnati Hemant Shah, Jae Ho Lo, Steve Soto Trujillo, Yitzhar Goretsky, Wu Zhang, Alan P. Venook, Sandra Algaze, Joshua Millstein, Heinz-Josef Lenz. Correlation of mitophagy related genes expression and clinical outcome in metastatic colorectal cancer patients enrolled in CALGB (Alliance)/SWOG 80405 [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2026; Part 1 (Regular Abstracts); 2026 Apr 17-22; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(7 Suppl):Abstract nr 1011.
Abstract 449: Albumin-based DLL3-targeted nano-immunoconjugates of SN38 preserve potency and demonstrate high-affinity DLL3 binding in small cell lung cancer.
Shanshal, Mohamed , Yang, Lin, Geng, Liyi, Nevala, W., Mansfield, Aaron S., Leventakos, Konstantinos , Nevala, Wendy N., Mansfield, Aaron S., Wootla, Bharath , Korshavn, Kyle J. , Markovic, Svetomir N.

Mayo Clinic

Cancer Research | April 3, 2026 | Volume: 86 | Issue: 7_Supplement | Pages: 449-449

10.1158/1538-7445.am2026-449 Get It

Abstract Background: Small cell lung cancer (SCLC) remains an aggressive malignancy with limited treatment options and a 5-year survival rate under 10%. Delta-like ligand 3 (DLL3), expressed in >85% of SCLC but absent from normal tissue, represents an attractive therapeutic target. Existing DLL3-directed antibody-drug conjugates suffer from poor payload stability and limited tumor penetration. To overcome these limitations, we engineered a DLL3-targeted nano-immunoconjugate (NIC) of SN38, the active metabolite of irinotecan, using an albumin-based nanoscaffold. Methods: SN38 was encapsulated in a human serum albumin (HSA) matrix and non-covalently coated with a recombinant anti-DLL3 monoclonal antibody to yield DLL3-SN38-NIC. Stable conjugation was confirmed by HSA-IgG interactions and zeta-potential shift. Binding kinetics were evaluated using Biacore surface plasmon resonance (SPR) and Octet bio-layer interferometry (BLI) employing AHC biosensors to determine DLL3-antibody affinity and specificity. Cytotoxicity was assessed using IncuCyte live-cell imaging across five SCLC cell lines (DMS454, SHP77, NCI-H82, NCI-H889, and NCI-H211) with varying DLL3 expression. Results: DLL3-SN38-NIC retained high-affinity DLL3 binding (KD ≈ 3 × 10-10 M) and demonstrated potent cytotoxicity in SCLC cell lines. NIC formation did not reduce cytotoxic activity compared with free SN38, confirming preserved potency. Cytotoxicity trends were consistent across lines with variable DLL3 expression, and DLL3 antibody alone exhibited negligible cytotoxicity. These findings confirm that nano-immunoconjugate formation maintains drug activity and DLL3 binding; additional in-vivo studies are underway to evaluate pharmacokinetics and tumor selectivity. Conclusions: Albumin-based DLL3-SN38-NICs represent a novel nano-oncologic platform that preserves SN38 potency and achieves high-affinity DLL3 engagement. Ongoing studies will assess in-vivo selectivity, biodistribution, and therapeutic potential in DLL3-positive SCLC and other neuroendocrine malignancies. Citation Format: Mohamed Shanshal, Lin Yang, Liyi Geng, Wendy Nevala, Aaron S. Mansfield, Bharath Wootla, Konstantinos Leventakos, Kyle Korshavn, Svetomir N. Markovic. Albumin-based DLL3-targeted nano-immunoconjugates of SN38 preserve potency and demonstrate high-affinity DLL3 binding in small cell lung cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2026; Part 1 (Regular Abstracts); 2026 Apr 17-22; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(7 Suppl):Abstract nr 449.
Molecular Regulation of Cardiomyocyte Cell Cycle and Regeneration
Li, Fan , Son, Yura , Yang, Ming , Zhu, Wuqiang, Yang, Ming , Zhu, Wuqiang , Li, Faqin , Zhu, Wuqiang , Son, Yura

Mayo Clinic

Biology | April 2, 2026 | Volume: 15 | Issue: 7 | Pages: 568

10.3390/biology15070568 | PMID 41972571 Get It

The regulation of the cardiomyocyte cell cycle is central to understanding heart regeneration. In adult mammals, cardiomyocytes withdraw from the cell cycle, limiting their ability to proliferate and repair heart tissue after injury. This process is controlled by intrinsic genetic programs and extrinsic signals, which together restrict the regenerative response in mature hearts. Understanding the mechanisms that regulate cardiomyocyte cell cycle activity is therefore critical for advancing cardiac regenerative medicine. In this review, we provide a comparative and integrated overview of cardiomyocyte cell cycle regulation in lower vertebrates and mammals, and discuss the major intrinsic factors that govern this process, including cyclin/CDK pathways, transcription factors and co-activators, oxygen and metabolic regulation, and epigenetic mechanisms. We also review the influence of hormones and growth factors, as well as the supportive roles of nonmyocyte populations in heart regeneration. By integrating findings across species, developmental stages, and regulatory levels, these findings highlight the complex regulatory network controlling cardiomyocyte proliferation and provide insight into potential therapeutic strategies for stimulating cardiac repair in the adult mammalian heart.
Spatial ligand–receptor gene annotations carry conditional heritability association across human tissues
Yang, Chen, Chen, Jun, Zhang, Xianyang, Chen, Jun

Mayo Clinic

No container title available | April 1, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.03.29.715138 | PMID 41959167 Get It

Abstract Methods that map genetic risk to cells do not directly test whether spatially organized ligand–receptor (LR) gene annotations carry conditional heritability association. Here we introduce EdgeMap, which scores each gene by the spatial activity of its LR contexts in spatial transcriptomics data, maps these scores alongside cell-intrinsic annotations to SNP-level LD scores, and tests both jointly against GWAS summary statistics. Across 17 traits and five human tissues, edge z -scores are systematically higher in biologically matched tissues: all 15 traits with both matched and unmatched tissue classes show this ordering (median Δ z = 1.51 ; sign P = 3.1 × 10 −5 ), and 11 of 13 nominal-positive associations concentrate in the biologically matched set ( P = 1 × 10 −4 ). The pattern survives broad LR-gene-class and cell-type composition controls. Donor-level cross-section summaries, independent GWAS replication for LDL and CAD, and cell-segmented Visium HD liver data provide convergent support. A secondary analysis prioritizes constituent genes within active LR contexts; sixteen of 31 prioritized genes are absent from standard gene-level methods. These results establish spatially weighted LR-gene annotations as a complementary layer for interpreting complex-trait genetic architecture.
Investigating the impact of problematic evidence on clinical practice guidelines and associated patient outcomes (VITALITY Study II): protocol
Xu, Chang, Kanamori, Luis Furuya, Cao, Hong, Wang, Xinyi, Li, Sheyu, Wen, Tianmeng, Fan, Shiqi , Gu, Zhichun , Lin, Lifeng, Yisha, Zuhaer , Cristea, Ioana Alina, Du, Liang, Clark, Juli, Zeng, Linan, Fan, Zhaohu , Golder, Su, Murad, M Hassan, Lin, Houwen, Mol, Ben W, Vohra, Sunita, Doi, Suhail A, Li, Sheyu , Clark, Justin , Xu, Chang , Li, Sheyu , Lin, Lifeng , Clark, Justin , Golder, Su , Murad, M Hassan , Mol, Ben W , Furuya‐Kanamori, Luis , Loke, Yoon Kong , Wen, Tianmeng , Stone, Jennifer , Cristea, Ioana A. , Du, L. C. , Qin, Zongshi , Song, Yang , Chu, Haitao , Vohra, Sunita , Doi, Suhail A

Mayo Clinic

BMJ Open | March 31, 2026 | Volume: 16 | Issue: 3 | Pages: e115303

10.1136/bmjopen-2025-115303 | PMID 41916628 Get It

Introduction Increasing publication of fraudulent clinical trials poses a serious threat to evidence-based medicine. In the VITALITY Study I, we demonstrated that contamination by retracted trials significantly distorts evidence synthesis. The upcoming VITALITY Study II will take a step further and investigate how such problematic evidence undermines the credibility of guideline recommendations. Methods and analyses The VITALITY Study II will adopt a retrospective cohort design and will be structured as three work packages (WPs). To start with, a cohort of clinical practice guidelines (CPGs) that were contaminated by retracted trials and/or meta-analyses that included retracted trials will be established based on forward citation searching (WP1). Then, recommendations from these CPGs that used evidence from retracted trials and/or meta-analyses that synthesised these retracted trials will be re-evaluated after removing such problematic evidence, in terms of both the direction and strength of effect sizes (WP2). Finally, the subsequent impact on patient outcomes attributable to distorted recommendations will be estimated on a hypothetical population, measured by the number of expected benefit loss and the number of expected harm increment per 100 000 patients (WP3). Ethics and dissemination Formal ethical approval is not necessary for this study as it does not involve human or animal participants, nor does it involve the collection of primary data. We will disseminate the findings through publication in peer-reviewed journals and, whenever possible, presentations at academic conferences.
CLO26-104: TBCRC 050: A Phase 1b/2 Trial of Niraparib and Trastuzumab in HER2+ Metastatic Breast Cancer (MBC): Safety and Efficacy
Stringer-Reasor, Erica, Li, Yufeng , Zhang, Jianqing , Rocque, Gabrielle, Jones, Kyla R, O'Sullivan, C. C., Dees, Elizabeth Claire , Nanda, Rita, Hunter, Natasha, Clark, Amy S. , Wolff, Antonio, Krop, Ian E. , Lin, Nancy, Yang, Eddy S. , O'Sullivan, Ciara, Giridhar, Karthik, Stringer-Reasor, Erica , Rocque, Gabrielle B. , O’Sullivan, Ciara C. , Giridhar, Karthik V. , Hunter, Natasha B. , Wolff, Antonio C. , Rimawi, Mothaffar F.

Mayo Clinic

Journal of the National Comprehensive Cancer Network | March 27, 2026 | Volume: 24 | Issue: 3.5 | Pages: No page available

10.6004/jnccn.2025.7190 | PMID 42061438 Get It

High Soluble Tumor Necrosis Factor Receptor 2 in Serum Is Associated With Inferior Overall Survival Across Major Lymphoma Subtypes
Khurana, Arushi , Hayashi, Hikaru, Thach, Bethany J., Yang, Zhi Zhang, Negaard, Brianna J., Cerhan, James R., Novak, Anne J. , Habermann, Thomas M., Feldman, Andrew L., Parikh, S., Slager, Susan L., Ansell, Stephen M., Maurer, Matthew J., Faustman, D L, Habermann, Thomas M. , Cerhan, James R. , Cerhan, James R , Habermann, Thomas , Slager, Susan L , Ansell, Stephen M , Maurer, Matthew , Novak, Anne J , Hayashi, Hikaru, Gysbers, Brianna J. , Link, Brian K. , Feldman, Andrew L. , Parikh, Sameer A. , Slager, Susan L. , Ansell, Stephen M. , Maurer, Matthew J.

Mayo Clinic

American Journal of Hematology | March 27, 2026 | Volume: 101 | Issue: 6 | Pages: 1388-1397

10.1002/ajh.70293 | PMID 41891328 Get It

ABSTRACT Soluble tumor necrosis factor receptor 2 (sTNFR2) is a member of the TNF superfamily whose normal bodily distribution is largely limited to low level expression on lymphoid cells. It has emerged as an important inducible receptor that activates a signaling pathway for cancer growth. We evaluated sTNFR2 as a prognostic biomarker for overall survival (OS) in newly diagnosed lymphoma using a prospective cohort study with banked pretreatment serum samples. sTNFR2 was higher in 1513 lymphoma patients compared to 499 age and sex matched controls ( p < 0.0001). Using Kaplan–Meier curves and Cox proportional hazards models to estimate hazard ratios [HR] (high vs. low tertile), higher levels of sTNFR2 at diagnosis were associated with inferior OS across all seven major lymphoma subtypes: Hodgkin lymphoma ( p < 0.0001; HR = 12.6), diffuse large B‐cell lymphoma ( p < 0.0001; HR = 2.6), follicular lymphoma ( p = 0.00017; HR = 2.5), mantle cell lymphoma ( p < 0.0001; HR = 4.2), small lymphocytic lymphoma ( p = 0.012; HR = 2.4), marginal zone lymphoma ( p = 0.0012; HR = 3.1), and T‐cell lymphoma ( p < 0.0001; HR = 3.1). Using CITE‐seq profiling of tumor microenvironment tissue, we sought to identify cellular source(s) of circulating sTNFR2. In tumor tissue from follicular lymphoma, high TNFR2‐expressing cells were found to be T‐regulatory (Treg) cells, suggestive of a Treg‐driven cancer. In tissue from a case of marginal zone lymphoma, high TNFR2 expression was found on CD4+ and CD8+ T cells, B cells, and monocytes but also directly on tumor cells. We conclude sTNRF2 is a strong prognostic biomarker of OS across major lymphoma subtypes and may be useful to guide therapeutic choices, including targeted therapies against immunosuppressive TNFR2‐expressing Tregs.